Research programme: antibacterials - Protez Pharmaceuticals

Drug Profile

Research programme: antibacterials - Protez Pharmaceuticals

Alternative Names: Antibacterials for slow-growing and biofilm bacteria - Protez Pharmaceuticals; Bacteriocidal potentiators research programme - Protez Pharmaceuticals; Efflux pump inhibitors research programme - Protez Pharmaceuticals; INF 401; INF-271,468; Research programme: bacteriocidal potentiators - Protez Pharmaceuticals; Research programme: efflux pump inhibitors - Protez Pharmaceuticals

Latest Information Update: 06 Jun 2008

Price : $50

At a glance

  • Originator Protez Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Gram-positive infections

Most Recent Events

  • 06 Jun 2008 Discontinued - Preclinical for Gram-positive infections in USA (unspecified route)
  • 23 Sep 2005 This programme is still in active development - BIO-2005 Annual International Convention (BIO-2005)
  • 02 Mar 2004 Influx has been acquired by, and merged into, Protez Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top